ReviewBMC cancer2025
Orbital natural killer/T-cell lymphoma: a comprehensive case series and literature review.
Review in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Ocular Manifestations Associated with Hematologic Malignancies: Mechanisms, Diagnosis, and Management.Medical sciences (Basel, Switzerland) · 2026Review
- Extranodal nasal-orbital communicating lesions NK/T cell lymphoma with ocular symptoms as the initial manifestation misdiagnosed as sinusitis and orbital cellulitis: a case report and literature review.Frontiers in oncology · 2026Article
- Article
- Primary Orbital Extranodal NK/T-Cell Lymphoma: A European Case Report.Case reports in ophthalmologyArticle
- Primary Orbital Extranodal Natural Killer/T-Cell Lymphoma in a Young African Male: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate the clinical features, pathological findings, treatment, and prognosis of patients with orbital natural killer/T-cell lymphoma (NKTCL).
methodsThis retrospective study collected clinical data from 11 patients diagnosed with orbital NKTCL by pathological examination at Beijing Tongren Hospital, Capital Medical University, between November 2005 and March 2024. The patients were followed up to assess their prognosis.
resultsThe median age of patients with orbital NKTCL was 51 years, with a slight male predominance. All cases were unilateral, with clinical presentations of eyelid or periorbital swelling, and other symptoms including decreased vision (90.9%), conjunctival congestion (90.9%), ocular motility disorders (81.8%), proptosis (63.6%), and ptosis (36.4%). All patients had surrounding tissue involvement, with the most common sites being the eyelid (11 cases), eyeball wall (7 cases), and lacrimal gland (5 cases). Additionally, 63.6% of patients had concurrent soft tissue involvement of the nasal region, while 36.4% had isolated orbital NKTCL. Pathological examination revealed diffuse proliferation and infiltration of atypical lymphocytes, occasionally with necrosis. Immunohistochemical staining showed positive expression of GrB (11 cases), CD3 (10 cases), TIA1 (9 cases), CD56 (8 cases), and EBV/EBER (10 cases). All patients underwent ocular surgery, 7 received postoperative chemotherapy, and one received concurrent local radiotherapy. Follow-up (median duration: 120 months) revealed poor prognosis, with 5 patients lost to follow-up, 5 deaths, and only one survival without recurrence.
conclusionsOrbital NKTCL is highly aggressive, rapidly progressive, and has a poor prognosis. Its clinical symptoms are similar to orbital cellulitis or inflammatory pseudotumor. When anti-inflammatory and corticosteroid therapies prove ineffective, early biopsy for histopathological confirmation is strongly recommended. Upon diagnosis, prompt chemotherapy and radiotherapy should be initiated to improve the patient's prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.